Mylan Recalls Tolterodine Tartrate Tablets Due to Impurity Failures
Mylan Pharmaceuticals is recalling 9,225 bottles of Tolterodine Tartrate Tablets, 1 mg, because the product failed impurity specifications for lactol and total impurities.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling 9,225 bottles of Tolterodine Tartrate Tablets, 1 mg, 60 Tablet Bottles, Rx only. The product is identified by NDC 0378-5445-91. The recall involves Lot # 2004069 and Lot # 2004070, both with an expiration date of 09/2014.
The recall was initiated because the product failed impurities and degradation specifications, specifically testing out of specification for lactol and total impurities. The FDA has classified this recall as Class III, which indicates that use of or exposure to the violative product is not likely to cause adverse health consequences.
The affected product was distributed nationwide in the United States. Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above. If the product is found, it should be returned to the pharmacy or point of purchase for disposal or credit in accordance with standard recall procedures.
The recalled product
- Product
- Tolterodine Tartrate Tablets, 1 mg, 60 Tablet Bottles, Rx only. Mylan Pharmaceuticals Inc., Morgantown, WV 26505. NDC: 0378-5445-91.
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 9,225
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # 2004069
- Expiry: 09/2014
- Lot #: 2004070
- Expiry: 09/2014.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17